Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Combined With Radiation for Malignant Brainstem Glioma
NCT04668508Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Nov 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in brainstem glioma, sponsored by Zhejiang Cancer Hospital. Primary endpoints: Disease Control Rate at 1 year, 6-month Progression-Free Survival Rate and 1 more. Status: unknown.
02
Drugs
anlotinib
03
Conditions
brainstem glioma
Beyond the preview
Go deeper on NCT04668508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04668508.